See more : Calcol, Inc. (CLCL) Income Statement Analysis – Financial Results
Complete financial analysis of Kindred Biosciences, Inc. (KIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindred Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Flexium Interconnect, Inc. (6269.TW) Income Statement Analysis – Financial Results
- Mondee Holdings, Inc. (MONDW) Income Statement Analysis – Financial Results
- Ken Holding Co., Ltd. (300126.SZ) Income Statement Analysis – Financial Results
- Zealand Pharma A/S (ZLDPF) Income Statement Analysis – Financial Results
- Flowerkist Skin Care and Cosmetics, Inc. (FKST) Income Statement Analysis – Financial Results
Kindred Biosciences, Inc. (KIN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.kindredbio.com
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.16M | 4.26M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.63M | 587.00K | 324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.54M | 3.67M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.03% | 86.21% | 83.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.28M | 28.31M | 26.40M | 17.67M | 13.86M | 19.41M | 18.69M | 3.14M | 75.00K |
| General & Administrative | 21.98M | 37.93M | 22.08M | 11.90M | 6.84M | 6.86M | 8.54M | 1.08M | 45.00K |
| Selling & Marketing | 0.00 | 0.00 | 4.42M | 2.08M | 1.47M | 992.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.98M | 37.93M | 26.50M | 13.99M | 8.31M | 7.85M | 8.54M | 1.08M | 45.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.26M | 66.24M | 52.90M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Cost & Expenses | 57.89M | 66.82M | 53.22M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Depreciation & Amortization | 4.68M | 2.54M | 805.00K | 475.00K | 155.00K | 146.00K | 58.00K | 3.13K | 0.00 |
| EBITDA | -15.29M | -58.85M | -48.89M | -30.40M | -22.34M | -26.98M | -27.08M | -4.21M | -120.00K |
| EBITDA Ratio | -36.27% | -1,382.75% | -2,486.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.97M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Operating Income Ratio | -47.36% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -56.00 | 0.00 |
| Income Before Tax | -21.80M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Income Before Tax Ratio | -51.69% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Net Income | -23.62M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Net Income Ratio | -56.03% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| EPS Diluted | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| Weighted Avg Shares Out | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
| Weighted Avg Shares Out (Dil) | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
Charles Schwab Investment Management Inc. Has $822,000 Position in Kindred Biosciences Inc (NASDAQ:KIN)
Charles Schwab Investment Management Inc. boosted its holdings in Kindred Biosciences Inc (NASDAQ:KIN) by 11.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,845 shares of...
A Single X-Ray Strike Is Enough to Destroy an Entire Molecule
Radiation damage spreads among close neighbors: A single soft x-ray can destroy a protein-sized molecule. A single x-ray can unravel an enormous molecule, physicists report in the March 17 issue of Physical Review Letters. Their findings could lead to safer...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test)...
Kindred Biosciences (NASDAQ:KIN) Shares Down 27.8% After Earnings Miss
Kindred Biosciences Inc (NASDAQ:KIN) traded down 27.8% during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings. The company traded as low as $3.76 and last traded at $4.34, 641,999 shares traded hands during mid-day trading....
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
Brokerages Set Kindred Biosciences Inc (NASDAQ:KIN) PT at $14.79
Shares of Kindred Biosciences Inc (NASDAQ:KIN) have been assigned an average rating of “Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have...
Kindred Biosciences (NASDAQ:KIN) Stock Rating Lowered by BidaskClub
Kindred Biosciences (NASDAQ:KIN) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, BidAskClub reports. A number of other brokerages also recently commented on KIN. Guggenheim downgraded...
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
Robôs ajudam em combate e prevenção contra o coronavírus; FOTOS
Ao redor do mundo, pandemia do Covid-19 tem motivado uso de robôs para evitar contato humano, e também para tratar a solidão de quem precisa se isolar. Robôs com máscara e produtos de higiene são usados para conscientização sobre o...
Kindred Biosciences (KIN) Receives a Buy from H.C. Wainwright
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Kindred Biosciences (KIN), with a price target of
Source: https://incomestatements.info
Category: Stock Reports